{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:10Z","timestamp":1784543050158,"version":"3.55.0"},"reference-count":53,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>This study, conducted at two university-based infectious disease clinics, included 216 patients with chronic hepatitis C. The primary objective was to assess the positive and negative predictive values, sensitivity, and specificity of achieving a sustained virological response (SVR) at 4 weeks compared to 12 weeks post-therapy. The results demonstrated a maximum sensitivity of 100% for achieving SVR at 12 weeks after reaching SVR at 4 weeks for all analyzed genotypes, except for genotype 1b treated with EBR\/GZR therapy, where the specificity was 75%. Additionally, younger age and less advanced liver fibrosis were identified as independent predictors of achieving a sustained virological response at both 4 and 12 weeks. The significant normalization of various biochemical parameters was observed after treatment, indicating an overall improvement in liver function. This study suggests that shortening the monitoring period to 4 weeks might be effective for younger patients without significant fibrosis, potentially reducing loss to follow-up, which is a critical issue in HCV treatment. These findings align with the \u201ctest and treat\u201d approach. Further research is needed to confirm these findings and incorporate them into official guidelines, which could simplify and enhance the effectiveness of HCV treatment protocols, aiding global efforts to eliminate HCV as a public health issue by 2030.<\/jats:p>","DOI":"10.3390\/microorganisms12102050","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:34:36Z","timestamp":1728560076000},"page":"2050","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing Hepatitis C Treatment Monitoring: Is Sustained Virologic Response at 4 Weeks Becoming the New Standard?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-3328","authenticated-orcid":false,"given":"Ivana","family":"Milo\u0161evi\u0107","sequence":"first","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Filipovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Beronja","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-7307","authenticated-orcid":false,"given":"Nikola","family":"Mitrovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1820-9067","authenticated-orcid":false,"given":"Maja","family":"Ru\u017ei\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Clinic for Infectious Diseases, University Clinical Centre of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Simi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Kne\u017eevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pete","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Clinic for Infectious Diseases, University Clinical Centre of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-1067","authenticated-orcid":false,"given":"Nevena","family":"Todorovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Nikoli\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Bulevar Oslobo\u0111enja 16, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciaa144","article-title":"Evaluation of sustained virologic response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection","volume":"72","author":"Krassenburg","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","first-page":"79","article-title":"Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review","volume":"6","author":"Axley","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Suhail, M., Sohrab, S.S., Kamal, M.A., and Azhar, E.I. (2022). Role of Hepatitis C Virus in Hepatocellular Carcinoma and Neurological Disorders: An Overview. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.913231"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/liv.14834","article-title":"Is Elimination of HCV in 2030 Realistic in Central Europe","volume":"41","author":"Flisiak","year":"2021","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir\u2013Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","article-title":"Effectiveness of Elbasvir and Grazoprevir Combination, with or without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection","volume":"152","author":"Kwo","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chen, R., Xiong, Y., Zeng, Y., Wang, X., Xiao, Y., and Zheng, Y. (2023). The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: A systematic review and network meta-analysis. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1179531"},{"key":"ref_10","unstructured":"WHO (2024, July 10). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2016.06."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/liv.15150","article-title":"Road to Elimination of HCV: Clinical Challenges in HCV Management","volume":"42","author":"Hayes","year":"2021","journal-title":"Liver Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"g7809","DOI":"10.1136\/bmj.g7809","article-title":"Is Widespread Screening for Hepatitis C Justified?","volume":"350","author":"Koretz","year":"2015","journal-title":"Br. Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep4.1646","article-title":"Innovations in Hepatitis C Screening and Treatment","volume":"5","author":"Patel","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0040-1713657","article-title":"Simplification of Care for Chronic Hepatitis C Virus Infection","volume":"40","author":"Pawlotsky","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"The Lancet Gastroenterology Hepatology (2022). Simplifying the Path to Elimination of Hepatitis C. Lancet Gastroenterol. Hepatol., 7, 781.","DOI":"10.1016\/S2468-1253(22)00247-3"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0973-6247.126683","article-title":"Hepatitis C Virus: Screening, Diagnosis, and Interpretation of Laboratory Assays","volume":"8","author":"Gupta","year":"2014","journal-title":"Asian J. Transfus. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3855\/jidc.10190","article-title":"FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C\u2014A developing country\u2019s perspective in DAA era","volume":"12","author":"Karic","year":"2018","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13337-020-00592-0","article-title":"HCV Genotypes and Their Determinative Role in Hepatitis C Treatment","volume":"31","author":"Keikha","year":"2020","journal-title":"VirusDisease"},{"key":"ref_20","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., and AASLD-IDSA HCV Guidance Panel (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., ciad319."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S2468-1253(20)30366-6","article-title":"The Phases of Hepatitis C Elimination: Achieving WHO Elimination Targets","volume":"6","author":"Pedrana","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable","volume":"16","author":"Dhiman","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gnanapandithan, K., and Ghali, M.P. (2023). Self-Awareness of Hepatitis C Infection in the United States: A Cross-Sectional Study Based on the National Health Nutrition and Examination Survey. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0293315"},{"key":"ref_24","unstructured":"World Health Organization (WHO) (2024, July 10). Global Hepatitis Report 2017. Available online: http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jhep.2016.08.002","article-title":"Who to Test and How to Test for Chronic Hepatitis C Infection\u20142016 WHO Testing Guidance for Low- and Middle-Income Countries","volume":"65","author":"Easterbrook","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.jhepr.2022.100531","article-title":"Impact of the COVID-19 Pandemic on Hepatitis B and c Elimination: An EASL Survey","volume":"4","author":"Kondili","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jvh.13399","article-title":"Loss to Follow-up in the Hepatitis C Care Cascade: A Substantial Problem but Opportunity for Micro-Elimination","volume":"27","author":"Dijk","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1093\/ofid\/ofaa439.1255","article-title":"1069. Loss to Follow-up Does Not Impact SVR for HCV Infection","volume":"7","author":"Kottilil","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0033354918776641","article-title":"A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017","volume":"133","author":"Moore","year":"2018","journal-title":"Public Health Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e000181","DOI":"10.1136\/bmjgast-2017-000181","article-title":"Barriers to Care for Chronic Hepatitis C in the Direct-Acting Antiviral Era: A Single-Centre Experience","volume":"4","author":"Nguyen","year":"2017","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1007\/s10620-018-5247-5","article-title":"Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C","volume":"63","author":"Marshall","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jvh.12943","article-title":"Real-World Outcomes of Unrestricted Direct-Acting Antiviral Treatment for Hepatitis C in Australia: The South Australian Statewide Experience","volume":"25","author":"Haridy","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/00365521.2018.1467963","article-title":"Direct Acting Antiviral Treatment of Chronic Hepatitis C in Denmark: Factors Associated with and Barriers to Treatment Initiation","volume":"53","author":"Hallager","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/jvh.13274","article-title":"Network-Based Recruitment of People Who Inject Drugs for Hepatitis C Testing and Linkage to Care","volume":"27","author":"Ward","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jvh.13233","article-title":"Hepatitis C Virus Testing, Liver Disease Assessment and Treatment Uptake among People Who Inject Drugs Pre- and Post-Universal Access to Direct-Acting Antiviral Treatment in Australia: The LiveRLife Study","volume":"27","author":"Bajis","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3138\/canlivj.1.2.002","article-title":"Diagnosis and Treatment of Hepatitis C Virus Infection: A Tool for Engagement with People Who Inject Drugs in Vancouver\u2019s Downtown Eastside","volume":"1","author":"Alimohammadi","year":"2018","journal-title":"Can. Liver J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/QAD.0000000000001566","article-title":"Successful Implementation of Hepatitis C Virus Treatment in Two Large HIV Clinics in Amsterdam","volume":"31","author":"Saris","year":"2017","journal-title":"AIDS"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e25197","DOI":"10.1002\/jia2.25197","article-title":"Previous Incarceration Impacts Access to Hepatitis C Virus (HCV) Treatment among HIV-HCV Co-Infected Patients in Canada","volume":"21","author":"Kronfli","year":"2018","journal-title":"J. Int. AIDS Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"ofaa085","DOI":"10.1093\/ofid\/ofaa085","article-title":"Hepatitis C Care Continuum in a Human Immunodeficiency Virus (HIV) Positive Cohort: Data from the HIV Atlanta Veterans Affairs Cohort Study","volume":"7","author":"Adekunle","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ofz070","DOI":"10.1093\/ofid\/ofz070","article-title":"Predictors of Hepatitis C Treatment Failure after Using Direct-Acting Antivirals in People Living with Human Immunodeficiency Virus","volume":"6","author":"Cachay","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_41","unstructured":"Allen, R., Artz, L., Bryans, S., Birk, M., Kozma, J., L\u00f3pez, M., Ferrer, J., and Podmore, M. (2024, July 10). GLOBAL PRISON TRENDS Penal Reform International Global. Available online: https:\/\/cdn.penalreform.org\/wp-content\/uploads\/2015\/04\/PRI-Prisons-global-trends-report-LR.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.4103\/jfmpc.jfmpc_788_22","article-title":"A Retrospective Study to Find the Prevalence of HIV, HCV and Dual HIV-HCV Infection in the Prison Inmates","volume":"11","author":"Swu","year":"2022","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, Management, and Treatment of Hepatitis C: An Update","volume":"49","author":"Ghany","year":"2008","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2014). EASL Clinical Practice Guidelines: Management of Hepatitis C Virus Infection. J. Hepatol., 60, 392\u2013420.","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and so Much More","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between Sustained Virological Response and All-Cause Mortality among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","article-title":"Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies","volume":"144","author":"Chen","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of Sustained Virological Response 4, 12, and 24 Weeks Post-Treatment with Sofosbuvir-Containing Regimens for Hepatitis C Virus","volume":"61","author":"Yoshida","year":"2014","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Andreoni, M., Coppola, N., Crax\u00ec, A., Fagiuoli, S., Gardini, I., Mangia, A., Nava, F.A., and Pasqualetti, P. (2022). Meet-Test-Treat for HCV Management: Patients\u2019 and Clinicians\u2019 Preferences in Hospital and Drug Addiction Services in Italy. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-021-06983-y"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jvh.13634","article-title":"Point-of-Care Hepatitis C Testing and Treatment Strategy for People Attending Harm Reduction and Addiction Centres for Hepatitis C Elimination","volume":"29","author":"Forns","year":"2022","journal-title":"J. Viral Hepat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jvh.13600","article-title":"Positive Predictive Value of Sustained Virologic Response 4 Weeks Posttreatment for Achieving Sustained Virologic Response 12 Weeks Posttreatment in Patients Receiving Glecaprevir\/Pibrentasvir in Phase 2 and 3 Clinical Trials","volume":"28","author":"Gane","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ferreira, J., Bicho, M., and Serejo, F. (2024). Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic\/Cellular Parameters. Viruses, 16.","DOI":"10.3390\/v16030371"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e29675","DOI":"10.1002\/jmv.29675","article-title":"Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals","volume":"96","author":"Liu","year":"2024","journal-title":"J. Med. Virol."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/10\/2050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:10:48Z","timestamp":1760112648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/10\/2050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["microorganisms12102050"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms12102050","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}